EMMA insider buying and SEC filings, explained
Emmaus Life Sciences, Inc. · CIK 822370
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- OTC
- Industry (SIC)
- Pharmaceutical Preparations
- State of incorporation
- DE
- Fiscal year end
- Dec 31
- Former names
- MYnd Analytics, Inc.; CNS RESPONSE, INC.; STRATIVATION, INC.; SalesTactix, Inc.; AGE RESEARCH INC
Insider activity in the last 12 months
Bought
$18K
Insiders who bought
1
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$0
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| May 30, 2025–Aug 31, 2026 | Purchase (code P) | Willis C. Lee (CEO and Director) bought 530,767 shares indirectly (by retirement or benefit plan) between May 30, 2025 and Aug 31 at about $0.0342 ($18K), reported as a purchase (code P). Holdings by retirement or benefit plan up 333% to 690,167 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 2, 2026 |
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow EMMA in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.